Search
Osimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalOsimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung canc...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesThiosulfuric acid
go.drugbank.com/drugs/DB09499ApprovedInvestigationalThiosulfuric acid is available in its salt forms sodium thiosulfate and sodium thiosulfate pentahydrate. Sodium thiosulfate is part of the World Health Organization’s list of essential medicines, and it has a variety of industrial uses, ...
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Enzyme InducersCetylpyridinium
go.drugbank.com/drugs/DB11073ApprovedInvestigationalCetylpyridinium is a quaternary ammonium with broad-spectrum antiseptic properties. Its salt form, cetylpyridinium chloride, is typically found as an active ingredient in mouthwashes, toothpastes, lozenges, throat sprays, breath sprays, ...
Mixtures: NORAVER P TABLETAS DE DISOLUCIÓN BUCAL, NORAVER P TABLETAS DE DISOLUCIÓN BUCALPeppermint oil
go.drugbank.com/drugs/DB11198ApprovedInvestigationalExtracted from the stem, leaves, and flowers of Mentha piperita L. plant, peppermint oil (Mentha piperita) is a popular essential oil used in aromatherapy for both external and internal use. Mentha piperita is a hybrid of spearmint (Ment...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP3A InhibitorsDihydro-alpha-ergocryptine
go.drugbank.com/drugs/DB11274ApprovedAlpha-dihydroergocryptine is usually referred to the mixture of the alpha and beta dihydroergocryptine. These two compounds are differentiated in the position of a methyl group. This structural difference is due to a proteinogenic amino ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesGrazoprevir
go.drugbank.com/drugs/DB11575ApprovedGrazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that i...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesAsunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnAsunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor. It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genoty...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesVelpatasvir
go.drugbank.com/drugs/DB11613ApprovedInvestigationalVelpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus ...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsArtenimol
go.drugbank.com/drugs/DB11638ApprovedInvestigationalArtenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated Plasmodium falciparum infections [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2011 in com...
Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2D6 InhibitorsVinflunine
go.drugbank.com/drugs/DB11641ApprovedInvestigationalVinflunine is a third-generation member of the vinca alkaloid family with anti-tumour actions. It was first described in 1998 at the Pierre Fabre research center in France. Like other vinca agents, vinflunine is an anti-mitotic agent tha...
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates